Shurrab M, et al. - In this systematic review and meta-analysis, researchers explored the connection between long-term vitamin K antagonists (VKAs), one of the most commonly used anticoagulation therapies, use and cancer risk. From inception until January 2018, systematic searches of multiple major databases were conducted. Adult studies comparing the incidence of any cancer between ≥ 6 months use of VKAs (long-term group) and < 6 months use of VKAs or nonuse (control group) were included. Participants in the study were 1,521,408 patients. According to findings, long-term VKAs use, for any indication, was linked to a lower incidence of cancer. This finding may have significant clinical implications in choosing oral anticoagulation therapies among specific patients with higher baseline cancer risk.